N Engl J Med · 2023
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
In a phase-2 randomised trial, participants receiving retatrutide showed dose-dependent reductions in body weight over 48 weeks.
View on PubMed (PMID 37366315)